Pathology: mML - L2 - all population;
mML - L2 - all population | ||||||||||||
CA184-004, 2011 | Ascierto (ipi 10 vs 3 mg/kg), 2017 | MDX010 Ipi vs gp100, 2010 | MDX010 Ipi plus gp100 vs gp100, 2010 | MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 | CA184-024, 2011 | CheckMate 037, 2015 | KEYNOTE-006 (3 week), 2015 | KEYNOTE-002 (10 mg/kg), 2015 | KEYNOTE-006 (2 week), 2015 | KEYNOTE-002 (2 mg/kg), 2015 | ||
pembrolizumab (10mg/kg) | 2 | T1 | T1 | |||||||||
Ipilimumab (10 mg/kg) | 2 | T1 | T1 | |||||||||
ipilimumab plus gp100 | 2 | T1 | T1 | |||||||||
nivolumab alone | 1 | T1 | ||||||||||
pembrolizumab (10mg/kg) 2 weeks | 1 | T1 | ||||||||||
pembrolizumab (2mg/kg) | 1 | T1 | ||||||||||
ipilimumab alone | 1 | T0 | T0 | T1 | T0 | T0 | T0 | |||||
ipilimumab plus SoC | 1 | T1 | ||||||||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | ||||||||
placebo plus SoC | 0 | T0 | ||||||||||
gp100 | 0 | T0 | T0 |